AUTHORS
Anya Lia Eden Reinin Platt, MD, Vanessa A. Fabrizio, MD, MS2, Andrew Nicklawsky, MS3, Hisham Abdel-Azim, MD, MS4, Osama Abuhasheesh, MBBS5, Etai Adam, MD6, Muhammad Ali, MBBS7, Eric Anderson, MD8, Victor Aquino, MD9, Amir Reza Pashmineh Azar, MBS10, Jaap Jan Boelens, MD, PhD11, Emi Caywood, MD12, Rohini Chakravarthy, MD, MPH13, Soohee Cho, MD, MSCS14, Eleanor Cook, MBBS15, Neysimelia Costa Villela, MD16, Laurie Davis, MD, PhD17, Patrick Demartino, MD, MPH18, Gretchen Eames, MD19, William Ferguson, MD20, Christopher Fraser, MBBS, FRACP21, Melissa Gabriel, MBBS, FRACP22, Rabi Hanna, MD23, Emily Hsieh, MD24, Zahra Hudda, MD25, Jeffrey Huo, MD26, Susan Kelly, MD27, Madhavi Lakkaraja, MD,MPH28, Kris Mahadeo, MD29, Theodore Moore, MD30, Megan M. Murphy, MD31, Kevin Owen McNerney, MD, MSc32, Courtney Pette, MD33, April Rahrig, DO, MS34, Hemalatha Geetharani Rangarajan I, MD35, Shanti Ramachandran, MBBS, MD, FRACP36, Ravi M Shah, MBBS, MD, RCPSC Specialist37, Molly Shields, MD38, Ali Suliman, MD, MSc39, Nicholas Tastet, BS40, Franziska Wachter, MD41, Randy M. Windreich, M.D.42, Lauren Wilson, DO43, Ashley Woodruff, RN, BSN44, Troy C. Quigg, DO45, Alix E. Seif, MD, MPH46, Heather J. Symons, MD47, Elliot Stieglitz, MD48
AFFILIATIONS
1 UCSF Benioff Children's Hospitals, San Francisco, California, United States
2 Children's Hospital Colorado, Aurora, Colorado, United States
3 University of Colorado Anschutz, Denver, Colorado, United States
4 Loma Linda University Children's Hospital, Loma Linda, California, United States
5 Medical University of South Carolina, Charleston, South Carolina, United States
6 Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
7 The Hospital for Sick Children, Toronto, Ontario, Canada
8 Rady Children's Hospital San Diego/UCSD, San Diego, California, United States
9 UT Southwestern Medical Center Dallas, Dallas, Texas, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Lisa Dean Moseley Institute of Cancer and Blood Disorders, Nemours Children’s Health Wilmington, DE and Sidney Kimmel Medical College, Thomas Jefferson University, Wilmington, Delaware, United States
13 University of Chicago/Comer Children’s Hospital, Chicago, Illinois, United States
14 Intermountain Health Primary Children's Hospital and Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
15 Minderoo Children's Comprehensive Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia
16 Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
17 Baylor College of Medicine, CHRISTUS Children's, San Antonio, Texas, United States
18 Oregon Health & Science University, Portland, Oregon, United States
19 Cook Children's Medical Center, Fort Worth, Texas, United States
20 Saint Louis University School of Medicine and SSMHealth Cardinal Glennon Children's Hospital, St. Louis, Missouri, United States
21 Queensland Children's Hospital, South Brisbane, Queensland, Australia
22 Children's Hospital at Westmead, Sydney, New South Wales, Australia
23 Cleveland Clinic Children's, Cleveland, Ohio, United States
24 Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, California, United States
25 Cincinnati Children's Hospital Medical Center, University of Cincinnati Department of Pediatrics, Cincinnati, Ohio, United States
26 Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
27 AdventHealth Orlando, Orlando, Florida, United States
28 Fred Hutch Cancer Center, University of Washington School of Medicine, Seattle, Washington, United States
29 Duke Children's, Durham, North Carolina, United States
30 UCLA Mattel Children's Hospital, Los Angeles, California, United States
31 John Hopkins University, Baltimore, Maryland, United States
32 Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
33 Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States
34 Indiana University, Riley Hospital for Children, Indianapolis, Indiana, United States
35 Nationwide Children's Hospital, Columbus, Ohio, United States
36 Perth Children's Hospital, Perth, Australia
37 Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada
38 Children's Hospital of Los Angeles, Los Angeles, California, United States
39 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
40 Atrium Health Levine Children's Hospital, Charlotte, North Carolina, United States
41 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, United States
42 UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
43 Children's Mercy Hospital, Kansas City, Missouri, United States
44 Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
45 Corewell Health Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
46 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
47 John Hopkins University, Baltimore, Maryland, United States
48 UCSF Benioff Children's Hospitals, San Francisco, California, United States
ABSTRACT
Introduction
Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myeloproliferative neoplasm. Even though a minority of patients experience spontaneous regression, hematopoietic stem cell transplant (HCT) remains the only established curative therapy. While matched related (MRD) and unrelated donor transplantation have been well described, outcomes following haploidentical (haplo) HCT are restricted to small case series. Additionally, despite advances in supportive care over the past two decades, contemporary outcomes for JMML patients transplanted during this period remain poorly defined.
Methods
We conducted an international, multicenter retrospective analysis to characterize HCT outcomes across donor sources in the modern era, with a particular focus on haplo HCT. Patients aged 0-10 years with JMML undergoing first HCT between 2010-2023 at 42 participating sites (34 US sites and 8 international) were included. Baseline characteristics and outcomes were summarized descriptively. Overall survival (OS), event free survival (EFS), disease-free survival (DFS), and graft-vs-host disease (GVHD)/relapse-free survival (GRFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cumulative incidence of relapse (CIR), treatment-related mortality (TRM), and primary graft failure (GF) were performed using competing-risk methods with Gray’s test. Acute and chronic GVHD were compared using Pearson’s chi-square tests.
Results
A total of 166 patients (70% male) underwent HCT. Median age was 22 months (range 2-142) at diagnosis and 29 months (range 5-137) at first HCT. Patients were predominantly white (72%) and 19% were of Hispanic/Latino ethnicity. Eighty-three percent (n=136) of patients received pre-HCT therapy, including cytarabine-based regimens (55%), fludarabine-based regimens (44%), and azacitidine-based regimens (28%); categories were not mutually exclusive. Busulfan-based myeloablative conditioning was used in 95% of patients. Donor sources included MRD (n=33, 20%), matched unrelated donor (MUD; n=63, 38%), mismatched unrelated donor (MMUD; n=14, 8.5%), haplo donor (n=21,13%), and umbilical cord blood (UCB; n=34, 22%) Among haplo recipients (n=21), 62% received post-HCT cyclophosphamide (PTCy) and 33% underwent αβ T-cell depletion. Graft sources included bone marrow (58%), peripheral blood (20%) and UCB (22%).
After a median follow-up of 5.9 years (range, 0.1-15.6), 74% of patients were alive. HCT complications included GF (8.4%), acute GVHD (44%), chronic GVHD (14%), veno-occlusive disease (41%), and transplant-associated thrombotic microangiopathy (6.6%). Thirty-three patients (20%) required a 2nd HCT, most commonly for relapse (64%). Among deaths (n=41), TRM accounted for 51% and relapse for 37%.
The study cohort had a 2-year OS of 80.2%, DFS of 68.8%, EFS of 64.0%, and GRFS of 33.6%. Differences in OS by donor source did not reach statistical significance (p = 0.061), and haplo HCT outcomes were comparable to other donor sources, with 2-year OS, DFS, EFS, and GRFS of 76.2%, 71.4%, 57.1%, and 47.6%, respectively. There were no differences between 2-year DFS (p=0.411), EFS (p=0.139), or GRFS (p=0.179) when comparing donor sources. Two-year CIR varied by donor source (MRD 33.6%, MUD 22.4%, MMUD 15.4%, haplo 19.0%, UCB 11.8%; p=0.063). Compared with all alternative donor sources combined, MRD transplantation was associated with a higher CIR (33.6% vs 18.3%, p=0.010), while DFS remained similar (66.4% vs 69.4%, p=0.472). TRM differed by donor source (p<0.001), driven largely by higher 2-year TRM in UCB (32.4%) compared with MRD (0%), MUD (3.2%), MMUD (7.7%), and haplo (9.5%). Following haplo HCT, the incidence of acute GVHD (33%) and chronic GVHD (9.5%) were comparable to other donor sources (p=0.205 and p=0.537), with no differences between αβ-depletion and PTCy platforms (acute GVHD p=0.696; chronic GVHD p=0.507).
Conclusions
In this large, international multicenter cohort of children with JMML, contemporary HCT outcomes demonstrate favorable long-term survival across donor sources. Haplo HCT achieved encouraging transplant outcomes, supporting its role as an effective alternative donor strategy. Although historically considered the standard for HCT in JMML, MRD HCT was associated with a higher CIR compared with alternative donor sources combined, but this did not translate into inferior DFS, highlighting the need for further investigation into factors influencing survival risk in JMML.
DISCLOSURES
Vanessa A. Fabrizio, MD, MS: adaptimmune - Consultancy (Includes expert testimony)